AVNR » Topics » Fair value of financial instruments

These excerpts taken from the AVNR 10-K filed Dec 17, 2008.
Fair value of financial instruments
 
At September 30, 2008 and 2007, the Company’s financial instruments included cash and cash equivalents, receivables, investments in marketable securities, accounts payable, accrued expenses, and accrued compensation and payroll taxes and long-term borrowings. The carrying amount of cash and cash equivalents, receivables, accounts payable, accrued expenses and accrued compensation and payroll taxes approximates fair value due to the short-term maturities of these instruments. The Company’s short- and long-term investments in marketable securities are carried at fair value based on quoted market prices. The fair value of the Company’s notes payable and capital lease obligations were estimated based on quoted market prices or pricing models using current market rates. At September 30, 2008 and 2007, the fair value of the Company’s notes payable and capital lease obligations approximate the carrying value of the notes.
 
Fair
value of financial instruments



 



At September 30, 2008 and 2007, the Company’s
financial instruments included cash and cash equivalents,
receivables, investments in marketable securities, accounts
payable, accrued expenses, and accrued compensation and payroll
taxes and long-term borrowings. The carrying amount of cash and
cash equivalents, receivables, accounts payable, accrued
expenses and accrued compensation and payroll taxes approximates
fair value due to the short-term maturities of these
instruments. The Company’s short- and long-term investments
in marketable securities are carried at fair value based on
quoted market prices. The fair value of the Company’s notes
payable and capital lease obligations were estimated based on
quoted market prices or pricing models using current market
rates. At September 30, 2008 and 2007, the fair value of
the Company’s notes payable and capital lease obligations
approximate the carrying value of the notes.


 




This excerpt taken from the AVNR 10-K filed Dec 21, 2007.
Fair value of financial instruments
 
At September 30, 2007 and 2006, our financial instruments included cash and cash equivalents, receivables, investments in marketable securities, accounts payable, accrued expenses, accrued compensation and payroll taxes and long-term borrowings. The carrying amount of cash and cash equivalents, receivables, accounts payable,


F-11


Table of Contents

 
Avanir Pharmaceuticals
 
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
 
accrued expenses and accrued compensation and payroll taxes approximates fair value due to the short-term maturities of these instruments. Our short- and long-term investments in marketable securities are carried at fair value based on quoted market prices. The fair value of our notes payable and capital lease obligations were estimated based on quoted market prices or pricing models using current market rates. At September 30, 2007 and 2006, the fair value of our notes payable approximate the carrying value of the notes.
 
This excerpt taken from the AVNR 10-K filed Dec 18, 2006.
Fair value of financial instruments
 
At September 30, 2006 and 2005, our financial instruments included cash and cash equivalents, receivables, investments in securities, accounts payable, accrued expenses, accrued compensation and payroll taxes and long-term borrowings. The carrying amount of cash and cash equivalents, receivables, accounts payable, accrued expenses and accrued compensation and payroll taxes approximates fair value due to the short-term maturities of these instruments. Our short- and long-term investments in securities are carried at fair value based on quoted market prices. The fair value of our notes payable and capital lease obligations were estimated based on quoted market prices or pricing models using current market rates. At September 30, 2006 and 2005, the fair value of our notes payable were approximately $25.3 million and $825,000, respectively.
 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki